Genprex Taps Andelyn Biosciences to Accelerate Manufacturing Scale-Up for Diabetes Gene Therapy Program

Contract Pharma USA

Overview

Clinical-stage company Genprex has selected Andelyn Biosciences as its CDMO to scale up manufacturing for its diabetes gene therapy program. Leveraging its proprietary Curator Cell and Gene Therapy Platform, Andelyn will provide comprehensive clinical-stage manufacturing services, including process optimization and scale-up, to facilitate IND submissions. This partnership is crucial for advancing Genprex’s innovative gene therapy towards clinical trials and potential patient access.

In Depth

Background

Gene therapy holds immense potential for treating chronic diseases like diabetes, which affects millions globally. However, translating these complex biological therapies from research concepts to clinical reality requires highly specialized manufacturing capabilities that can ensure product quality, consistency, and scalability under stringent regulatory requirements. Clinical-stage companies often partner with Contract Development and Manufacturing Organizations (CDMOs) to access these critical resources and expertise.

Key Findings

• Genprex, a clinical-stage biotechnology company, has chosen Andelyn Biosciences as its CDMO partner.
• The primary objective of this collaboration is to scale up the manufacturing processes for Genprex’s diabetes gene therapy program.
• Andelyn Biosciences will utilize its proprietary Curator Cell and Gene Therapy Platform to support this initiative.
• The services provided by Andelyn include:
  • Process optimization to enhance efficiency and yield.
  • Strategic scale-up activities to meet clinical demand.
  • Support for Investigational New Drug (IND) submissions to regulatory authorities.
• These comprehensive clinical-stage manufacturing services are designed to propel Genprex’s gene therapy candidate through development.

Significance & Outlook

The selection of Andelyn Biosciences by Genprex signifies a critical step forward for the diabetes gene therapy program. Efficient and scalable manufacturing is often a major bottleneck in the development of advanced therapeutic medicinal products (ATMPs). By partnering with a specialized CDMO like Andelyn, Genprex can leverage external expertise and infrastructure, thereby accelerating its path to clinical trials and potential market entry. This collaboration underscores the increasing importance of robust manufacturing partnerships in the gene therapy sector, particularly for chronic, widespread conditions like diabetes. Successful scale-up will be crucial for the therapy’s eventual accessibility and affordability, potentially offering a transformative treatment option for diabetic patients worldwide.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime